Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Touza JL"'
Autor:
Porreca I; Revvity, 8100 Cambridge Research Park, Cambridge CB25 9TL, UK. Electronic address: immacolata.porreca@revvity.com., Blassberg R; Revvity, 8100 Cambridge Research Park, Cambridge CB25 9TL, UK., Harbottle J; Revvity, 8100 Cambridge Research Park, Cambridge CB25 9TL, UK., Joubert B; Revvity, 8100 Cambridge Research Park, Cambridge CB25 9TL, UK., Mielczarek O; Revvity, 8100 Cambridge Research Park, Cambridge CB25 9TL, UK., Stombaugh J; Revvity, 2650 Crescent Drive, Lafayette, CO 80026, USA., Hemphill K; Revvity, 2650 Crescent Drive, Lafayette, CO 80026, USA., Sumner J; AstraZeneca, Discovery Sciences, R&D, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Pazeraitis D; AstraZeneca, Discovery Sciences, R&D, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Touza JL; AstraZeneca, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Pepparedsleden 1, 431 83 Mölndal, Sweden., Francescatto M; AstraZeneca, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Pepparedsleden 1, 431 83 Mölndal, Sweden., Firth M; AstraZeneca, Discovery Sciences, R&D, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Selmi T; Revvity, 8100 Cambridge Research Park, Cambridge CB25 9TL, UK., Collantes JC; Departamento de Biotecnología, Colegio de Ciencias Biológicas y Ambientales, Universidad San Francisco de Quito, Campus Cumbayá, Casilla Postal 17-1200-841, Quito 170901, Ecuador., Strezoska Z; Revvity, 2650 Crescent Drive, Lafayette, CO 80026, USA., Taylor B; AstraZeneca, Discovery Sciences, R&D, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK., Jin S; Pharmacology Department, Rutgers, The State University of New Jersey, Robert Wood Johnson Medical School, 675 Hoes Lane West, Piscataway, NJ 08854, USA., Wiggins CM; Revvity, 8100 Cambridge Research Park, Cambridge CB25 9TL, UK., van Brabant Smith A; Revvity, 2650 Crescent Drive, Lafayette, CO 80026, USA., Lambourne JJ; Revvity, 8100 Cambridge Research Park, Cambridge CB25 9TL, UK.
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2024 Aug 07; Vol. 32 (8), pp. 2692-2710. Date of Electronic Publication: 2024 Jun 26.
A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo.
Autor:
Bestas B; Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden., Wimberger S; Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden.; Department of Chemistry & Molecular Biology, University of Gothenburg, Gothenburg, Sweden., Degtev D; Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden., Madsen A; Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden., Rottner AK; Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden., Karlsson F; Data Sciences and Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Cambridge, UK., Naumenko S; Department of Biostatistics, Harvard Chan School of Public Health, Boston, MA, USA., Callahan M; Translational Genomics, Translational Medicine, R&D Oncology, AstraZeneca, Waltham, MA, USA., Touza JL; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden., Francescatto M; Data Sciences and Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Cambridge, UK., Möller CI; Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden., Badertscher L; Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden., Li S; Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden., Cerboni S; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Selfjord N; Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden., Ericson E; Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden., Gordon E; Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden., Firth M; Data Sciences and Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Cambridge, UK., Chylinski K; Vienna Biocenter Core Facilities, Vienna Biocenter (VBC), Vienna, Austria., Taheri-Ghahfarokhi A; Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden., Bohlooly-Y M; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden., Snowden M; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Pangalos M; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Nuttall B; Translational Genomics, Translational Medicine, R&D Oncology, AstraZeneca, Waltham, MA, USA., Akcakaya P; Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden., Sienski G; Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden. grzegorz.sienski@astrazeneca.com., Maresca M; Genome Engineering, Discovery Sciences, BioPharmaceuticals R&D Unit, AstraZeneca, Gothenburg, Sweden. marcello.maresca@astrazeneca.com.
Publikováno v:
Nature communications [Nat Commun] 2023 Sep 06; Vol. 14 (1), pp. 5474. Date of Electronic Publication: 2023 Sep 06.